36
Participants
Start Date
June 30, 2011
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)
Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)
Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
Placebo
Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
Malaria Clinical Trials Center at Seattle Biomedical Research Institute, Seattle
The PATH Malaria Vaccine Initiative (MVI)
OTHER
Seattle Children's Hospital
OTHER
Crucell Holland BV
INDUSTRY